Biosimilars

The Alliance of Community Health Plans calls for changes to get more biosimilars approved and on the market.

Texas Oncology Executive Vice President Debra Patt says it will be unrealistically expensive for oncologists to keep many biosimilars for the same innovator product in their inventories.

Authors of a review say biosimilars would improve treatment, not just reduce cost.

Whether the OCM has worked out is debatable, but it has apparently encouraged the use of biosimilar versions of filgrastim.

It's early days yet because patent and other issues have kept FDA-approved biosimilars off the market, but Gary Lyman, M.D., M.P.H.. of the Fred Hutchinson Cancer Research Center says there's evidence of some effect on the price of cancer supportive drugs.

Advocates say a number of regulatory changes could help bring more of these products on to the market.

Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.

Vote in May made FDA-approved biosimilars an "appropriate substitution" for brand-name biologics in NCCN guidelines.

Along with the other Humira biosimilars, Hulio will not be on the market till 2023.

Pacific Research Institute’s Winegarden Sees Dose of Competition as Way to Lower OOP Costs

Cardinal Health recently conducted a survey of more than 100 rheumatologists asking their feelings about biosimilars, and the findings revealed that the majority of them were familiar with and comfortable prescribing biosimilars. 

Proving therapeutic equivalence is a major hurdle.

Developing a biosimilar can be more challenging than developing the innovator product because of the need to match the attributes of a highly complex molecules.

The purpose of biosimilar is simple: reduce healthcare costs, pure and simple. Here are 11 trends affecting biosimilars over the last year in the U.S.

Just as we’ve seen the entire healthcare landscape change in 2020 because of  COVID-19, the world of biosimilars is ever-changing. 

Several biosimilars will come to market within the next few years.

Study finds that biologics that faced competition from biosimilars showed reductions in net prices and leveling off of list price increases.

The FDA Commissioner says that insurers can help biosimilar adoption by taking short-term financial losses over long-term drug savings. What else should they be doing?

The Biosimilars Forum, in partnership with Medicines for Europe, says the U.S. can look to European policy directives to advance the biosimilars market.

The falsehoods being spread about biosimilars that don’t match up with reality.

The FDA issued a lengthy statement on biosimilar naming conventions-but industry groups worry it could disincentivize biosimilar development.

Industry groups are calling for clear FDA guidance on language used by biologic originators to protect market share.

What the future of specialty drugs holds for healthcare.

The latest in RA therapies, and what you can expect from the pipeline.

Biosimilar drugs are poised to transform the cancer drug market-so why is uptake so slow?

As more biosimilar agents are approved by the FDA, biologic manufacturers are looking for unique ways to hold on to market share.

While still largely a new phenomenon, biosimilars are here to stay-and this year will only bring more of them to market.

Biosimilar adoption is not happening as fast as once expected-will fears about future growth hold the market back?